Capstone (CAPS) vs HCW Biologics (HCWB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Capstone is the larger company by market cap ($3.6 million vs $3.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CAPS | HCWB |
|---|---|---|
| Share price | $0.1372 | $1.60 |
| Market cap | $3.62M | $3.58M |
| 1-day change | -2.63% | +4.58% |
| EPS (TTM) | $-3.32 | $-19.84 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.36 | $27.57 |
| 52-week low | $0.13 | $1.50 |
| Distance from 52-week high | -89.91% | -94.20% |
| Analyst consensus | none | buy |
| Avg. price target upside | +2086.59% | +2900.00% |
| Average volume | 4.35M | 376.23K |
| Shares outstanding | 26.38M | 2.24M |
| Employees | 93 | 35 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Capstone
CAPS stock →Capstone Holding Corp., through its subsidiaries, engages in the distribution and installation of building products in the United States and Canada. It operates in two segments, TotalStone and Carolina Stone.
Health Care · Biotechnology: Pharmaceutical Preparations · 93 employees
About HCW Biologics
HCWB stock →HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 35 employees
CAPS vs HCWB FAQ
Which is bigger, Capstone or HCW Biologics?
Capstone (CAPS) is larger, with a market capitalization of $3.62M compared with $3.58M for HCW Biologics (HCWB).
Are Capstone and HCW Biologics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.